ClinicalTrials.gg
RecruitingNCT07101991NCHGDTUpdated Oct 15, 2026

Effects of GDHT (Goal Directed Hemodynamic Therapy) Using a Non-invasive Hemodynamic Monitoring in Elective Neurosurgery

An interventional study of Standard monitoring and Goal-Directed Therapy in Surgery Complications, sponsored by Brno University Hospital. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Brno University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 15, 2026Now RecruitingFirst site in Czechia+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to assess the safety and efficacy of GDHT using the non-invasive Starling™ SV System in elective neurosurgery. The tested group of patients (n=70) will be compared with a control group (n=70), where hemodynamic management will be guided by standard vital signs monitoring.

Read the detailed description

Patients undergoing major surgery are at risk for inadequate intravascular volumes and therefore inadequate tissue perfusion and oxygen delivery. Especially in neurosurgery, fluid management can be a challenge. In many surgical areas, such as orthopedics, gynecology or abdominal surgery, goal-directed fluid therapy is used with the aim of reducing postoperative complications. Current knowledge regarding effect of the goal-directed therapy in neurosurgery is limited.

This is a multicenter, prospective, randomized, controlled study that compares two approaches to fluid management in elective brain surgery. Patients scheduled for brain surgery will be screened whether they meet the inclusion criteria and after obtaining informed consent, the patient will be randomized to one of two study arms.

In the first (standard) arm standard vital signs monitoring will be used during the surgery and perioperative fluid management and administration of vasopressors will be guided by the decision of the attending anaesthetist.

In the second (GDT) arm perioperative fluid management and administration of vasopressors will be guided by a non-invasive hemodynamic monitor STARLINK™SV, which will be introduced in addition to standard monitoring.

The primary outcome is the incidence of adverse events and reactions according to following Adverse Events of Special Interest (AESI) in both study groups and their comparison. The secondary outcome is to investigate the efficacy and additional safety parameters of GDHT guided by non-invasive advanced hemodynamic monitoring versus hemodynamic management guided by standard vital signs monitoring.

This study will enroll 140 patients in total, 70 in each group. After completion of enrolment of patients the statistical analysis will be performed.

02

Conditions studied

  • Surgery Complications

Keywords

  • neurosurgery
  • goal-directed therapy
  • adverse events
03

In context

Lead sponsor

Brno University Hospital is the lead sponsor of 91 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects will be eligible for the trial if they meet all of the following criteria:

  • Age ≥ 18 years
  • Elective brain surgery with an expected duration ≥ 2 h
  • Category 1-3 according to the ASA () Physical Status Classification
  • Lateral or supine operative position
  • Signed the relevant form

Exclusion criteria

Exclusion Criteria:

Subjects will not be eligible for the trial if they meet any of the following criteria:

  • Category 4 according to the ASA Physical Status Classification
  • Surgery for traumatic brain injury or acute hemorrhagic stroke
  • Awake brain surgery
  • Osmotherapy before surgery (with the exception of prophylactic administration of osmotic agents according to institutional standards)
  • Unavailability of hemodynamic monitoring data
  • Cardiac arrhythmia with irregular cardiac rhythm
  • Known to the active substance or to any of the of IMP ( Medicinal Product)
  • Pregnancy and lactation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    Standard monitoring

    In this arm standard monitoring of vital signs will be used during operation.

    Other: Standard monitoring

  • Experimental
    Goal-Directed Therapy

    A non-invasive hemodynamic monitor STARLINK™SV will be used in addition to standard monitoring.

    Other: Goal-Directed Therapy

Interventions

  • OtherStandard monitoring

    Administration of fluids and vasoactive drugs guided by standard vital signs monitoring

  • OtherGoal-Directed Therapy

    Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring

06

What researchers measure

Primary outcomes

  1. Number of participants with acute kidney Injury

    Defined according to Kidney Disease Improving Global Outcomes (KDIGO) guidelines: Stage 1: serum creatinine 1.5-1.9 times baseline value within 7 days or ≥27 µmol l-1 (0.3 mg dl-1) increase within 48 h; urine output ≤0.5 ml kg-1 h-1 for 6-12 h Stage 2: serum creatinine 2.0-2.9 times baseline value within 7 days; urine output ≤0.5 ml kg-1 h-1 for 12 h Stage 3: serum creatinine 3.0 times baseline within 7 days or increase in serum creatinine to ≥354 µmol l-1 (≥4.0 mg.dl1 with an acute rise of \> 44 mmol l-1 (0.5 mg/dl-1) or initiation of renal replacement therapy or in patients \< 18 years, decrease in eGFR (estimated Glomerular Filtration Rate) to \< 35 ml min-1 per 1.73m2; urine output ≤0.3 ml kg1 h-1 for 24 h or anuria for 12 h. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  2. Number of participants with acute Respiratory Distress Syndrome (ARDS)

    The Berlin definition of Respiratory Distress Syndrome: Timing: Within one week of a known clinical insult or new or worsening respiratory symptoms and Chest imaging: Bilateral opacities not fully explained by effusions, lobar/lung collapse or nobles and Origin of oedema: Respiratory failure not fully explained by cardiac failure or fluid overload. Need objective assessment (e.g. echocardiography) to exclude hydrostatic oedema if no risk factor is presented and Oxygenation disorder: mild: PaO2 (partial pressure of oxygen in arterial blood):FIO2 (Fraction of Inspired Oxygen) between 26.7 and 40.0 kPa (kilopascal) (200-300mmHg) with PEEP (Positive End-Expiratory Pressure) or CPAP (Continuous Positive Airway Pressure) ≥5 cmH2O (centimeters of water). Moderate: PaO2:FIO2 between 13.3 and 26.6 kPa (100- 200 mmHg) with PEEP ≥5 cmH2O. Severe: PaO2:FIO2 ≤13.3 kPa (100mmHg) with PEEP ≥5 cmH2O. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  3. Number of participants with arrhythmia

    Defined as electrocardiograph (ECG) evidence of cardiac rhythm disturbance. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  4. Number of participants with cardiac arrest

    Cessation of cardiac mechanical activity, as confirmed by the absence of signs of circulation. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  5. Number of participants with cardiogenic pulmonary oedema

    Defined as evidence of fluid accumulation in the alveoli due to poor cardiac function. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  6. Number of participants with deep vein thrombosis (DVT)

    A new blood clot or thrombus within the venous system. Appropriate diagnostic tests include ultrasound, venography, CT or MRI venography. Plasma D-dimer measurement is not recommended as a diagnostic test in the first three weeks following surgery. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  7. Number of participants with pulmonary embolism (PE)

    A new blood clot or thrombus within the pulmonary arterial system. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  8. Number of participants with gastrointestinal bleed

    Clinical or endoscopic evidence of blood in the gastrointestinal tract. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  9. Number of participants with infection, source uncertain

    Infection where there is strong clinical suspicion of infection but the source has not been confirmed because clinical information suggests more than one possible site, meeting two or more of the following criteria: core temperature \< 36°C or \>38°C; white cell count \>12×109 l-1 or \< 4×109 l-1, respiratory rate \>20 breaths per minute or PaCO2 \< 4.7 kPa (35mmHg); pulse rate \>90 beats per minute. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  10. Number of participants with laboratory confirmed bloodstream infection

    Infection which meets at least one of the following criteria which should not be related to infection at another site: 1. Patient has a recognised pathogen cultured from one or more blood cultures and the organism cultured from blood is not related to an infection at another site. 2. Patient has at least one of the following signs or symptoms: fever \>38°C, chills or hypotension, and at least one of the following. 1. Common skin contaminant cultured from two or more blood cultures drawn on separate occasions. 2. Common skin contaminant cultured from at least one blood culture from a patient with an intravascular line, and the physician institutes appropriate antimicrobial therapy. 3. Positive blood antigen test. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  11. Number of participants with myocardial infarction

    Defined as increase in serum cardiac biomarker values (preferably cardiac troponin) with at least one value above the 99th percentile upper reference limit and at least one of the following criteria: symptoms of ischaemia; new or presumed new significant ST segment or T wave ECG changes or new left bundle branch block; development of pathological Q waves on ECG; radiological or echocardiographic evidence of new loss of viable myocardium or new regional wall motion abnormality; identification of an intracoronary thrombus at angiography or autopsy. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  12. Number of participants with pneumonia

    Definition: Two or more serial chest radiographs with at least one of the following (one radiograph is sufficient for patients with no underlying pulmonary or cardiac disease): 1. new or progressive and persistent infiltrates 2. consolidation 3. cavitation; at least one of the following: (1) fever (\>38°C) with no other recognised cause (2) leucopaenia (white cell count \< 4 × 109 l-1) or leucocytosis (white cell count \>12 × 109 l-1) (3) for adults \>70 years old, altered mental status with no other recognised cause; and at least two of the following: 1. new onset of purulent sputum or change in character of sputum, or increased respiratory secretions, or increased suctioning requirements 2. new onset or worsening cough, or dyspnoea, or tachypnoea 3. rales or bronchial breath sounds 4. worsening gas exchange (hypoxaemia, increased oxygen requirement, increased ventilator demand). AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  13. Number of participants with paralytic ileus

    Failure to tolerate solid food or defecate for three or more days after surgery. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  14. Number of participants with postoperative haemorrhage

    Blood loss within 72 h after the start of surgery which would normally result in transfusion of blood. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  15. Number of participants with stroke

    An embolic, thrombotic or haemorrhagic cerebral event with persistent residual motor, sensory or cognitive dysfunction (e.g. hemiplegia, hemiparesis, aphasia, sensory deficit, impaired memory). AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  16. Number of participants with brain oedema

    Brain oedema confirmed on CT or MRI scan. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  17. Number of participants with surgical site infection (superficial)

    A superficial incisional surgical site infection is defined as one which meets the following criteria: 1. Infection occurs within 30 days after surgery and 2. Involves only skin and subcutaneous tissue of the incision and 3. The patient has at least one of the following: 1. purulent drainage from the superficial incision 2. organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision 3. at least one of the following symptoms or signs of infection: pain or tenderness, localised swelling, redness or heat, and superficial incision is deliberately opened by surgeon and is culture positive or not cultured. A culture-negative finding does not meet this criterion. 4. diagnosis of an incisional surgical site infection by a surgeon or attending physician. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  18. Number of participants with surgical site infection (deep)

    1. Infection occurs within 30 days after surgery if no implant is left in place or 1 year if implant is in place. 2. Involves deep soft tissues (e.g. fascial and muscle layers) of the incision. 3. The patient has at least one of the following: 1. purulent drainage from the deep incision but not from the organ/space component of the surgical site 2. a deep incision spontaneously dehisces or is deliberately opened by a surgeon and is culture-positive or not cultured when the patient has at least one of the following symptoms or signs: fever (\>38°C), or localised pain or tenderness. A culture- negative finding does not meet this criterion. 3. an abscess or other evidence of infection involving the deep incision is found on direct examination, during surgery, or by histopathological or radiological examination 4. diagnosis of an incisional surgical site infection by a surgeon or attending physician. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  19. Number of participants with surgical site infection (organ/space)

    Infection which involves any part of the body excluding the fascia or muscle layers and meets the following criteria: 1. Infection occurs within 30 days after surgery. 2. The infection appears to be related to the surgical procedure and involves any part of the body, excluding the skin incision, fascia or muscle layers opened or manipulated during the operative procedure. 3. The patient has at least one of the following: 1. purulent drainage from a drain that is placed through a stab wound into the organ/space 2. organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space 3. an abscess or other evidence of infection involving the organ/space that is found on direct examination, during reoperation or by histopathological or radiological examination 4. diagnosis of an organ/space surgical site infection by a surgeon or attending physician. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

  20. Number of participants with urinary tract infection

    A positive urine culture of ≥105 colony forming units ml-1 with no more than two species of micro-organisms, and with at least one of the following symptoms or signs: fever (\>38°C), urgency, frequency, dysuria, suprapubic tenderness, costovertebral angle pain or tenderness with no other recognised cause. Each of these criteria should be identified within a 24-h period. AESI will be analysed descriptively and compared between study groups.

    Time frame: 28 days

Secondary outcomes

  1. Duration of surgery

    Duration of surgery (min) - will be analysed descriptively and compared between study arms

    Time frame: During the surgery (hours)

  2. Length of hospital stay

    LOS (Length of stay, day of admission - day of discharge will be counted as 1 day) - will be calculated as a number of days between admission and discharge, analysed descriptively and compared between study groups.

    Time frame: Days (up to 28)

  3. ICU length of stay

    ICU LOS (day of admission - day of discharge will be counted as 1 day) - will be calculated as a number of days between admission to the ICU and discharge from the ICU, analysed descriptively and compared between study groups.

    Time frame: Days (up to 28)

  4. 28-day mortality

    28-day mortality (number of patients who are not alive 28 days after randomization) will be evaluated as a number and percentage of patients who are not alive 28 days after randomization and compared between study arms.

    Time frame: 28 days after randomization

  5. Adverse events

    Descriptive analysis of the incidence of any adverse events and reactions

    Time frame: 28 days

  6. Hemodynamic characteristics - MAP (Mean arterial pressure)

    MAP (mmHg; before, after surgery) will be analysed descriptively and compared between study arms.

    Time frame: During the surgery and 24 hours post operation

  7. Hemodynamic characteristics - HR (Heart rate)

    HR (Bpm; before, after surgery) will be analysed descriptively and compared between study arms.

    Time frame: During the surgery and 24 hours post operation

  8. Hemodynamic characteristics - SVV (Stroke volume variation) measured by The Starling™ SV System

    SVV (%; before, after surgery will be analysed descriptively and compared between study arms.

    Time frame: During the surgery (hours)

  9. Hemodynamic characteristics - number of episodes of hypotension

    Number of episodes of hypotension will be analysed descriptively and compared between study arms.

    Time frame: During the surgery and 24 hours post operation

  10. Hemodynamic characteristics - number of vasopressor administrations

    Number of vasopressor administrations will be analysed descriptively and compared between study arms.

    Time frame: During the surgery and 24 hours post operation

  11. Hemoglobin

    Hemoglobin (g/l; before, after surgery and 24 hours after surgery) - will be analysed descriptively and compared between study arms.

    Time frame: 24 hours

  12. Plasma lactate level

    Plasma lactate level (mmol/L; before, after surgery and 24 hours after surgery) will be analysed descriptively and compared between study arms.

    Time frame: 24 hours

  13. Volume of blood loss

    Volume of blood loss (ml/kg; during surgery and in the 24-hour postoperative period) will be analysed descriptively and compared between study arms.

    Time frame: During the surgery and 24 hours post operation

  14. Urinary output

    Urinary output (ml/kg/hod; during surgery and in the 24-hour postoperative period) will be analysed descriptively and compared between study arms.

    Time frame: During the surgery and 24 hours post operation

  15. Number of administered units of packed RBC (Red blood cell)

    Number of administered units of packed RBC (during surgery and in the 24-hour postoperative period) will be analysed descriptively and compared between study arms.

    Time frame: During the surgery and 24 hours post operation

  16. Number of subjects receiving transfusion

    Number of subjects receiving transfusion (during surgery and in the 24-hour postoperative period) will be analysed descriptively and compared between study arms.

    Time frame: During the surgery and 24 hours post operation

  17. Crystalloid and colloid solutions consumption

    Crystalloid and colloid solutions consumption (type and total volume of infusion during surgery and in the 24-hour postoperative period) will be analysed descriptively and compared between study arms.

    Time frame: During the surgery and 24 hours post operation

  18. Boluses of crystalloids

    Boluses of crystalloids (ml; during surgery) will be analysed descriptively and compared between study arms.

    Time frame: During the surgery and 24 hours post operation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2025 (actual). Primary completion is estimated for Sep 2028, 33 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2025 → Dec 2025, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Aug 3, 2025
StartActual
Dec 1, 2025was Sep 2025
Primary completionEst.
Sep 2028
CompletionEst.
Nov 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
1 site added — first site in Czechia
Show site
  • The University Hospital Brno · Brno, Czechia
Oct 15, 2026
Start date
Sep 2025→Dec 1, 2025 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Czechia
    Show site
    • The University Hospital Brno · Brno, Czechia
    Start date Sep 2025→Dec 1, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07101991
Lead sponsor
Brno University Hospital
Collaborators
Military University Hospital, Prague, Zlin Regional Hospital
Responsible party
Roman Gal (Head of the department, Brno University Hospital) — Principal investigator
First posted
Aug 3, 2025
Start date
Dec 1, 2025
Primary completion
Sep 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Roman Gál, prof.
Contact
gal.roman@fnbrno.cz
+420 532 233 850
Ondřej Hrdý, M.D.
Contact
hrdy.ondrej@fnbrno.cz
+420 532 232 009
Veronika Kočí, M.D.
study chair · Brno University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion